Letter to the Editor
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment
Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario
Read
5504
Timeswas read the article
718
Total PDF
4786
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 May | 57 | 13 | 70 |
| 2025 April | 119 | 33 | 152 |
| 2025 March | 121 | 30 | 151 |
| 2025 February | 69 | 36 | 105 |
| 2025 January | 55 | 64 | 119 |
| 2024 December | 53 | 38 | 91 |
| 2024 November | 71 | 55 | 126 |
| 2024 October | 39 | 27 | 66 |
| 2024 September | 53 | 24 | 77 |
| 2024 August | 66 | 35 | 101 |
| 2024 July | 60 | 37 | 97 |
| 2024 June | 71 | 29 | 100 |
| 2024 May | 72 | 26 | 98 |
| 2024 April | 82 | 23 | 105 |
| 2024 March | 3392 | 32 | 3424 |
| 2024 February | 62 | 28 | 90 |
| 2024 January | 53 | 26 | 79 |
| 2023 December | 51 | 29 | 80 |
| 2023 November | 51 | 32 | 83 |
| 2023 October | 38 | 30 | 68 |
| 2023 September | 65 | 43 | 108 |
| 2023 August | 80 | 23 | 103 |
| 2023 March | 5 | 5 | 10 |
| 2022 August | 1 | 0 | 1 |
Show all
